Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)

Abstrakt

To investigate whether plasma galectin-3, a mediator of fibrogenesis, can identify patients with chronic heart failure (HF) for whom statins are effective.

Klíčová slova

• Heart failure
• lipids
• cardiovascular pharmacology
• atherosclerosis
• statins